@article{fdi:010066920,
  title = {{P}erspectives on benefit-risk decision-making in vaccinology : conference report},
  author = {{G}reenberg, {M}. and {S}imondon, {F}ran{\c{c}}ois and {S}aadatian-{E}lahi, {M}.},
  editor = {},
  language = {{ENG}},
  abstract = {{B}enefit/risk ({B}/{R}) assessment methods are increasingly being used by regulators and companies as an important decision-making tool and their outputs as the basis of communication. {B}/{R} appraisal of vaccines, as compared with drugs, is different due to their attributes and their use. {F}or example, vaccines are typically given to healthy people, and, for some vaccines, benefits exist both at the population and individual level. {F}or vaccines in particular, factors such as the benefit afforded through herd effects as a function of vaccine coverage and consequently impact the {B}/{R} ratio, should also be taken into consideration and parameterized in {B}/{R} assessment models. {C}urrently, there is no single agreed methodology for vaccine {B}/{R} assessment that can fully capture all these aspects. {T}he conference "{P}erspectives on {B}enefit-{R}isk {D}ecision-making in {V}accinology," held in {A}nnecy ({F}rance), addressed these issues and provided recommendations on how to advance the science and practice of {B}/{R} assessment of vaccines and vaccination programs.},
  keywords = {benefit/risk ; conference report ; vaccine ; methodology ; {EUROPE}},
  booktitle = {},
  journal = {{H}uman {V}accines and {I}mmunotherapeutics},
  volume = {12},
  numero = {1},
  pages = {176--181},
  ISSN = {2164-5515},
  year = {2016},
  DOI = {10.1080/21645515.2015.1075679},
  URL = {https://www.documentation.ird.fr/hor/fdi:010066920},
}